Roman Drai

Roman Drai


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Drug development & registration
Verified
Journal Article
Open access
PDF file
ILI. A. Lugovik
I. A. Lugovik
ABA. V. Babina
A. V. Babina
SAS. S. Arutyunyan
S. S. Arutyunyan
DED. О. Ermolaeva
D. О. Ermolaeva
VSV. B. Saparova
V. B. Saparova
ЯКЯ. К. Керученько
Я. К. Керученько
Introduction. Metabolic syndrome is a multifactorial complex of metabolic disorders accompanied by type 2 diabetes mellitus and abdominal obesity. In the pharmacological correction of obesity and type 2 diabetes mellitus, the greatest effect is demonstrated by dual agonists of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in particular tirzepatide. The original drug (Mundjaro, pln: tirzepatide) is not registered in the Eurasian Economic Union (EAEU), which limits its availability to patients and leads to the need to develop a domestic generic.Aim. Conducting a physicochemical and biological characterization of the drug Sejaro® (GP30931) in comparison with the original drug Mundjaro® to establish their comparability.Materials and methods. Three batches of each drug (solution for subcutaneous administration, 25 mg/ml) were studied. The primary structure was verified using high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS), peptide mapping and NMR (2D-NMR-1H-1H 1H/1H-TOCSY). Secondary structure, higher order structures and aggregation were assessed by circular dichroism (CD), high-resolution nuclear magnetic resonance (NMR), fluorescence quantum yield (FQY) and dynamic light scattering (DLS). Impurity profiles were analyzed using size-exclusion and reversed-phase HPLC. Functional activity was determined in cellular tests for activation of calcium currents through GLP-1 and GIP receptors with an assessment of the half-maximal effective concentration (EC50); equivalence was confirmed by the two-sided test (TOST, 90 % confidence interval).Results and discussion. HPLC-MS and mapping confirmed identical mass (4,810.52 Da) and amino acid sequence. NMR spectra, CD and CF profiles, and DLS were completely consistent, which allows us to conclude that the secondary and tertiary structures of the preparations are structurally identical. The content of all types of impurities in GP30931 did not exceed the Munjaro values. The difference in EC50 values for activation of GLP-1 and GIP receptors was ≤5 %, the comparative biological activity was within 0.80–1.25.Conclusion. The complex of studies conducted using orthogonal methods showed that "Sejaro" (GP30931) and "Mundjaro" are structurally identical, comparable in impurity profile and biologically equivalent. The obtained data make a significant contribution to the scientific substantiation of the equivalence of the reproduced drug tirzepatide and the reference original drug, thereby providing a reliable basis for further registration and clinical use of Sejaro® without conducting additional clinical studies.

9 January 2024 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
DBDmitry Bakulin
Dmitry Bakulin
EMEvgeny Morkovin
Evgeny Morkovin
VPV. I. Petrov
V. I. Petrov
ASA. V. Strygin
A. V. Strygin
ACA. N. Chumachenko
A. N. Chumachenko
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight the importance of glucagon-like peptide-1 (GLP-1) receptor agonists in the pharmacotherapy structure.The aim of the work was to review the literature regarding the physiology of GLP-1 and the therapeutic potential and development trends of its agonists.Materials and methods. The search for the review materials was carried out using the abstract databases of PubMed, Google Scholar and e-Library. The search was carried out for publications from 2000 to 2023, using the following keywords: “GLP-1”; “GLP-1R agonists”; “GIP”; “exenatide”; “liraglutide”; “dulaglutide”; “semaglutide”; “lixisenatide”; “albiglutide”; “taspoglutide” taking into account various spellings.Results. The interaction of almost all food components with enteroendocrine cells of the intestine leads to the secretion of incretins (primarily GLP-1) into the blood, triggering a complex of physiological reactions aimed primarily at the rapid utilization of incoming glucose (regulation of insulin and glucagon secretion), as well as the central regulation of dietary behavior (slowing gastric emptying and the formation of a feeling of satiety). A wide distribution of the GLP-1 receptor in various tissues and organs, its connection with intracellular signaling cascades aimed at launching energy-consuming remodeling (recovery) processes in endothelial cells, heart, neurons, beta cells, etc., is the basis for a wide range of pleiotropic effects of GLP-1 unrelated to its hypoglycemic effect. The discovery of synthetic GLP-1 receptor agonists with a long period of action has made it possible not only to therapeutically influence various parts of carbohydrate metabolism disorders, but also to increase the functional reserves of the target diabetes organs, reducing the risk of developing complications of the disease. Incretin-like drugs are well tolerated, with nausea being the most common side effect. The factors limiting a wider use of the drugs include their high cost and the preferred form of a subcutaneous solution. The current research is focused on the development of long-acting, oral, dual and triple agonists, fixed-dose combinations, and small molecule drugs.Conclusion. GLP-1 receptor agonists are a class of effective and safe drugs for the treatment of diabetes and obesity, which is rapidly developing in the most advanced areas of pharmacy. A further development of this group and the solution of the identified problems will open up new opportunities for the treatment of diabetes and its complications.

2 December 2020 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
AMAlexander Y. Mayorov
Alexander Y. Mayorov
RDRoman Drai
Roman Drai
TKTatiana Karonova
Tatiana Karonova
ОАОльга Ильинична Авдеева
Ольга Ильинична Авдеева
ИМИгорь Евгеньевич Макаренко
Игорь Евгеньевич Макаренко
ЮСЮлия Александровна Севастьянова
Юлия Александровна Севастьянова
Background: Prevention of the development of micro-and macrovascular complications in patients with diabetes melli-tus (DM) encouraged the search for insulin analogues that allow imitating, as close as possible, a normal physiological insulin secretion in healthy people. Biosimilars (bioanalogues of reference products) play an important role in the full provision with high-quality insulin medications throughout patients. The program of clinical trials of insulin bioanalogues includes pharmacology studies: pharmacokinetics (PK), pharmacodynamics (PD) and clinical safety research.Aims: To test whether RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) have similar PK and PD profiles in a hyperinsulinemic euglycaemic clamp (HEC) setting in patients with type 1 diabetes mellitus. Permission of the Ministry of Health of the Russian Federation No. 150 of 03/03/2016.Materials and methods: The study was conducted in 42 patients with type 1 diabetes aged 18 to 65 years. A doubleblind, randomized, crossover study of comparative PK and PD of drugs was chosen as a study design. The investigational products were injected after achieving a state of euglycemia before the HEC in a single dose of 0.6 U/kg subcutaneously into the subcutaneous fat of the anterior abdominal wall. During the study, regular blood sampling was performed, the amount of insulin glargine in the samples was determined by ELISA. The results are used to calculate the PK parameters and generate the concentration-time curves. The glucose infusion rate was corrected based on the measurement of glycemia. These data are used to calculate the PD parameters.Results: RinGlar® and Lantus® interventions have comparable PK and PD profiles in HEC setting in patients with type 1 diabetes. This is confirmed by the similarity of the main PK/PD parameters, PK/PD curves, and comparable safety. The confidence intervals of the geometric mean ratio were 81.02% - 120.62% for the PK parameter AUCins0-T, and 85.43% - 115.64% for the PD-parameter AUCGIR0_T, which fall within the specified limits of 80% - 125% to establish comparability between drugs.Conclusions: Results of the clinical trial demonstrate the biosimilarity of the products RinGlar® and Lantus®.

23 July 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
EME. V. Makarova
E. V. Makarova
VZV. I. Zvereva
V. I. Zvereva
AMA. R. Makarova
A. R. Makarova
DBDmitry Bakulin
Dmitry Bakulin
ASA. S. Shuvaeva
A. S. Shuvaeva
A significant part of patients with diabetes purchase sugar-lowering drugs (SLDs) on their own in retail pharmacy chains, and the market trends they generate represent an urgent area for this study.The aim. To study the turnover of hypoglycemic drugs, including insulins, in the commercial sector of the pharmaceutical market of the Russian Federation (RF) for 2020–2024.Materials and methods. The data presented in this article is based on a periodic retail audit conducted by the biotech company IQVIA. The period of 5 years (2020–2024) was covered. Data collection covered 33,613 commercial pharmacies in all regions of the RF (about 43% of pharmacies).Results. In the period from 2020 to 2023, a relatively stable increase in the volume of SLDs purchases was revealed, with small fluctuations, while in 2024 a significant leap in consumption was recorded, both in quantitative (packages) and in value (rubles) terms. During the entire monitoring period, the total volume of SLDs and insulin purchases in the retail market segment increased by more than 1.2 times, from 41.98 million packages in 2020 to 51.70 million in 2024. At the same time, the total procurement budget (at wholesale prices) increased by more than 2 times — from 19.40 to 41.57 billion rubles. The average price per package has also increased significantly, from 462 rubles in 2020 to 923 rubles in 2024, an increase of 1.7 times, reflecting significant inflation in the commercial pharmaceutical sector. In general, the Russian pharmaceutical market offers all variants of modern innovative hypoglycemic drugs (dipeptidyl peptidase-4 inhibitors [iDPP4], sodium-glucose cotransporter 2 inhibitors [iSGLT2], glucagon-like peptide-1 receptor agonists [arGPP-1]), which, according to general trends, demonstrate a steady increase in turnover. Older and less effective sulfonylureas and their combinations with metformin still occupy a significant market share. arGPP-1 group showed the greatest growth in quantity (11 times) and value (5 times), mainly due to the entry of Russian semaglutide analogues into the market. Government measures and investments in import substitution have led to a significant increase in the share of Russian drugs in purchases. Despite the positive dynamics of Russian production, import substitution in the SLDs segment has not achieved complete success and accounts for less than half of the turnover of hypoglycemic drugs.Conclusion. The growth of SLDs consumption in the retail segment of the RF in 2020–2024 has been revealed, especially due to the innovative drugs arGPP-1 and iNGLT2. Despite maintaining the leading position of metformin, the consumption structure is shifting towards more expensive schemes. The increase in the total procurement budget and the average package price highlights the need to expand preferential security programs. Import substitution has increased significantly over the indicated period, however, the share of domestic drugs is still less than half of the turnover.

24 January 2024 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
DKDenis Kurkin
Denis Kurkin
DBDmitry Bakulin
Dmitry Bakulin
ARA. I. Robertus
A. I. Robertus
YKYu. A. Kolosov
Yu. A. Kolosov
IKI. S. Krysanov
I. S. Krysanov
OIO. V. Ivanova
O. V. Ivanova
2021 marks the 100th anniversary of the discovery of insulin, an event that forever changed the lives of people with diabetes mellitus. At present patients around the world experience the miracle of insulin therapy every day. A disease that used to kill children and teenagers in 2 years in 1920 has become a disease that can be controlled with a possibility to lead a long productive life. Over the past century, the great discovery of Banting, Best and Collip has forever changed the world and saved millions of lives. This review is devoted to the history of the development of insulin and its further improvement: from the moment of discovery to the present days. Various generations of insulin are considered: from animals to modern ultrashort and basal analogues. The article ends with a brief review of current trends in the development of new delivery methods and the development of new insulin molecules. Over the past century, insulin therapy has come a long way, which has significantly improved the quality of life of our patients. But research is actively continuing, including in the field of alternative methods of insulin delivery, which are more convenient for the patient, as well as in the development of «smart» molecules that will have a glucose-dependent effect.

1 January 2021 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Closed access
AMAlexandr Y Mayorov
Alexandr Y Mayorov
AMAnna A Mosikian
Anna A Mosikian
DADiana N Alpenidze
Diana N Alpenidze
IMIgor E Makarenko
Igor E Makarenko
VOValeria L Orlova
Valeria L Orlova
RDRoman Drai
Roman Drai
Aim: To compare safety (immunogenicity) and efficacy of a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25) in Type 2 diabetes mellitus (T2D) patients. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 210 T2D patients, randomized 1:1 to twice-daily GP-Lis25 or Ly-Lis25. The primary end point was immune response at 26th week. Noninferiority margin for HbA1c was 0.4%. Results: Immune response frequency was similar in GP-Lis25 and Ly-Lis25 groups both at week 12 (p = 0.651) and 26 (p = 0.164). The difference of HbA1c change at week 26 was (95% CI) 0.01 (-0.27–0.28)%. Fasting plasma glucose, seven-point glucose profile and insulin dose were similar between groups. Safety did not differ between groups. Conclusion: GP-Lis25 and Ly-Lis25 demonstrated similar safety and efficacy. ClincalTrials.gov identifier: NCT04023344 .